The pharmaceutical equipment industry is supported by local policies and accelerates its development to the middle and high-end

【Pharmaceutical Network Market Analysis】Recently, Lianyungang City issued guidance on cultivating and expanding the leading industries in counties and districts, which clearly stated that the municipal development zone will focus on the development of new pharmaceutical industries, new material industries, equipment manufacturing industries, and new formats of service industries
.
Among them, for the new pharmaceutical industry, it is required to build and improve the biomedical research and development industry chain covering new drug design, characteristic raw materials, high-end excipient packaging materials, etc.
, develop and expand high-end chemical drugs, biological drugs, modern traditional Chinese medicine, high-end medical device industries, and cultivate pharmaceutical excipients, medicinal packaging materials, pharmaceutical equipment, special medical food, pharmaceutical services, cold chain logistics, medical health and other industries
.
Pharmaceutical equipment (picture source: pharmaceutical network) The pharmaceutical equipment industry belongs to the high-end manufacturing industry upgrade and encouragement field, which has attracted the attention of relevant national departments in recent years, and the favorable policies for the industry have also been continuously released
。 In January 2022, the Ministry of Industry and Information Technology and other nine departments jointly issued the "14th Five-Year Plan for the Development of the Pharmaceutical Industry", which focuses on the in-depth implementation of intelligent manufacturing, green manufacturing and quality improvement actions, improving the quality management level and product quality of drugs and medical devices throughout the life cycle, and promoting the high-end, intelligent and green development of the pharmaceutical industry; Recently, the Health Commission announced that it intends to use financial discount loans to renovate medical equipment, which will push domestic substitution to a new height again, and the industry believes that the field of pharmaceutical and pharmaceutical equipment will usher in a revaluation
of value.
Now that the industry is once again supported by local policies, it will accelerate its development to the middle and high-end, and at the same time, with the help of the epidemic and domestic substitution, the growth rate of the overall scale of the industry may be further accelerated
.
According to the data of China Insight Consulting, it is expected that by 2025, the scale of China's pharmaceutical equipment market will reach about 87.
5 billion yuan (excluding consumables, auxiliary materials, etc.
), and the compound growth rate from 2020 to 2025 will be about 10.
22%.
From the perspective of industrial development, in recent years, with the rise of new fields such as biological drugs and new therapies such as cell and gene therapy, the pharmaceutical equipment industry has ushered in a new round
of growth.
In addition, since 2020, domestic and foreign countries have entered the peak period of vaccine equipment procurement, and the domestic pharmaceutical equipment industry has gained new opportunities
due to factors such as limited import of equipment products and delayed delivery time.
Although the peak period brought by vaccines has gone, pharmaceutical equipment is in the upstream of the life science industry, and the industry generally believes that with the continuous improvement of the performance of domestic pharmaceutical machine products and the acceleration of the transformation to the middle and high-end, the market opportunity of domestic substitution is still an important opportunity period
for pharmaceutical machine enterprises.
In the face of domestic alternative new air outlets, some domestic pharmaceutical machine head enterprises with strength have been "rubbing their fists"
.
For example, Chutian Technology has basically completed the layout in the field of upstream cell culture of biological drugs, and has established Chu Tianyuan Chuang and Chu Tian Microspheres in the field of downstream isolation and purification of biological drugs, which are also actively layout
.
Chutian Technology's 2022 semi-annual report disclosed that due to factors such as domestic substitution, the company's new orders and orders in hand in the first half of this year were sufficient, and the annual new order target was not less than 10 billion yuan
。 Dongfulong, which is also optimistic about domestic substitution opportunities, announced in early August this year that it plans to raise no more than 3.
2 billion yuan for the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, the Zhejiang Dongfulong Biotechnology Co.
, Ltd.
life science industrialization base project, etc.
, and predicted in the registration draft that "in the future, more and more domestic pharmaceutical equipment manufacturers will further strengthen independent research and development, cut into the pharmaceutical industry chain in multiple links, and achieve import substitution
in all directions and in many fields.
" 。 The industry believes that from the perspective of the general trend, whether it is a national level or a local level of policy, it is expected to accelerate the process of domestic substitution, domestic substitution will become a major logic for the pharmaceutical equipment industry to maintain new growth, and enterprises with technology, customer resources and research and development capabilities are expected to embrace more opportunities
.
But also need to see that the current domestic pharmaceutical equipment industry is in the climbing period, some high-end pharmaceutical equipment such as reactors, separation and purification systems, etc.
are still occupied by foreign manufacturers in the main market, these areas will also need to be replaced by domestic production in the future, in general, the high-end development of domestic pharmaceutical equipment still has a long way to go
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.